Welcome to our dedicated page for EVTCY news (Ticker: EVTCY), a resource for investors and traders seeking the latest updates and insights on EVTCY stock.
Evotec SE (symbol: EVTCY) is a life science company based in Hamburg, Germany, with a unique business model focused on discovering and developing highly effective therapeutics. The company operates globally with over 5,000 employees and has strategic activities in neurology, oncology, metabolic, and infectious diseases. Evotec's multimodality platform combines innovative technologies, data, and science to create a world-leading co-owned pipeline for innovative therapeutics. The company collaborates with top pharmaceutical companies, biotech firms, academic institutions, and other healthcare stakeholders to deliver cutting-edge pharmaceutical products.
Evotec SE announced a contract with the U.S. Department of Defense valued up to $49.9 million for the rapid development of monoclonal antibody drug prototypes targeting plague. Under this contract, Just - Evotec Biologics will advance mAb prototypes from initial discovery to Phase I clinical trials using its J.DESIGN platform, which integrates AI and machine learning. The goal is to produce effective medical countermeasures against plague, enhancing national security. The work will take place at Evotec's Redmond, Washington facility, part of the DOD's Advanced Development and Manufacturing network.
Evotec has begun construction of its J.POD ® biologics manufacturing facility in Toulouse, France, expected to be operational in H2 2024. This facility will utilize advanced J.POD ® technology to enhance clinical and commercial manufacturing capacity for biologics, addressing challenges in traditional manufacturing methods. The project is backed by funding from the French government and the Occitanie Region and is anticipated to create over 150 high-skill jobs in the area.
Evotec operates globally and focuses on the development of therapeutics across various medical areas.
Evotec SE has announced its acquisition of Central Glass Germany GmbH from Central Glass Co. Ltd., enhancing its drug substance manufacturing capabilities. The fully operational facility in Halle/Westphalia, with a team of ~60 chemists, is EU cGMP certified, covering over 5,000 square meters. This strategic move aligns with Evotec's commitment to rare diseases and precision medicine, aiming for earnings accretion by 2023/24. The contract, signed on August 24, 2022, was at a purchase price of €1, and the transaction is set to close on November 1, 2022.
Evotec SE will release its financial results for the first half of 2022 on August 11, 2022. A conference call will be held at 02:00 PM CEST to discuss the outcomes and company performance. Dial-in details are provided for various countries, and a webcast with presentation slides will also be available on their website. Evotec is a life science company focused on developing innovative therapeutics across multiple therapeutic areas, boasting over 200 proprietary projects in its pipeline.
Evotec, Boehringer Ingelheim, and bioMérieux have announced a joint venture named Aurobac Therapeutics SAS to combat Antimicrobial Resistance (AMR). The venture aims to develop targeted antimicrobial therapies alongside actionable diagnostics, addressing a pressing public health issue that claims 1.27 million lives annually. Funded with €40 million, Aurobac leverages Evotec's expertise in drug discovery and bioMérieux's diagnostic prowess. This collaboration hopes to shift treatment strategies from broad-spectrum to precision medicine, enhancing global healthcare outcomes.
Evotec SE has completed the acquisition of Rigenerand Srl, a leading cell technology firm specializing in cGMP manufacturing of cell therapies. This acquisition enhances Evotec's EVO cells platform, providing increased capacity and expertise in the fast-evolving field of cell therapy. The new site in Modena, Italy, will facilitate the development and manufacturing of off-the-shelf iPSC-based therapies, ultimately aiming to address significant unmet medical needs. CEO Dr. Werner Lanthaler expressed confidence in the acquisition’s potential to accelerate innovative projects.
Evotec has announced the acquisition of Rigenerand Srl, a leading cell technology company, for €23 million. This move enhances Evotec's cell therapy platform by integrating high-quality cGMP manufacturing capabilities. Rigenerand, based in Italy, operates a state-of-the-art facility focused on cell therapy manufacturing. While initial revenue contributions are expected to be modest, the acquisition will strengthen Evotec's capabilities to secure new partnerships in the cell therapy sector. Both companies aim to leverage their combined expertise to advance innovative cell therapies.
Evotec SE and Sernova Corp. formed a strategic partnership to develop an iPSC-based beta cell replacement therapy for insulin-dependent diabetes. The collaboration aims to create a scalable, off-the-shelf therapy utilizing Evotec's QRbeta-derived iPSC-based beta cells and Sernova's Cell Pouch device, which enhances long-term cell survival. Evotec will invest €20 million (approx. CAD $27 million) in Sernova, with a profit-sharing arrangement upon commercialization. A joint conference call will occur on May 17, 2022, to discuss the partnership further.
Evotec SE has announced the extension and expansion of its partnership with Bristol Myers Squibb in the field of targeted protein degradation, originally established in 2018. This eight-year extension aims to develop a robust pipeline of molecular glue degraders. Evotec will utilize its EVO panOmics and EVO panHunter platforms for this endeavor. The company has received an upfront payment of $200 million, with potential total deal value reaching $5 billion, including additional royalties on product sales.
Evotec SE announced an 8-year extension and expansion of its strategic partnership with Bristol Myers Squibb, initially signed in 2018, to develop a pipeline of molecular glue degraders. The collaboration, leveraging Evotec's EVO panOmics and EVO panHunter platforms, includes an upfront payment of $200 million, with the potential for total deal value reaching $5 billion through performance-based payments and royalties on product sales.
FAQ
Where is Evotec SE based?
What is Evotec SE's business model?
How many employees does Evotec SE have?
What are Evotec SE's strategic activities?
Who does Evotec SE collaborate with?
